We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Elimination of CSCs as Potential Cure for Colon Cancer

By LabMedica International staff writers
Posted on 29 Jan 2018
Print article
Image: Colon cancer cells grown into three-dimensional organoids in a culture dish (Photo courtesy of Dr. Joseph Regan, Charité - Universitätsmedizin Berlin).
Image: Colon cancer cells grown into three-dimensional organoids in a culture dish (Photo courtesy of Dr. Joseph Regan, Charité - Universitätsmedizin Berlin).
Cancer researchers have identified a molecular pathway required by the cancer stem cells that underlie growth and development of colorectal tumors.

Colon cancer is a heterogeneous tumor driven by a subpopulation of cancer stem cells (CSCs). To study CSCs in colon cancer, investigators at Charité - Universitätsmedizin Berlin, Germany) used limiting dilution spheroid and serial xenotransplantation assays in mice to functionally define the frequency of CSCs in a panel of patient-derived cancer organoids. The aim was to eventually arrive at a treatment option that would cure colon cancer through the targeted elimination of cancer stem cells.

Results published in the December 5, 2017, issue of the journal Cell Reports showed that cancer organoids were enriched for CSCs, which varied in frequency between tumors. Whole-transcriptome analysis identified the WNT and Hedgehog signaling pathways as being enhanced in CSC-enriched tumors and in aldehyde dehydrogenase (ALDH)-positive CSCs. Furthermore, they showed that non-canonical Hedgehog signaling was a positive regulator of WNT signaling and was required for colon CSC survival.

"The targeted inhibition of the Hedgehog signaling pathway, used in combination with other standard treatments to shrink tumors, may provide a new strategy for the elimination of cancer stem cells and the prevention of cancer recurrence," said first author Dr. Joseph Regan, a researcher at Charité - Universitätsmedizin Berlin. "Future research will set out to better define the downstream signaling components of the pathway and further investigate how Hedgehog signaling controls cancer stem cell survival."

Related Links:
Charité - Universitätsmedizin Berlin

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.